Therefore, BCL-xL inhibition, besides a direct effect on HCC survival, may change the protumoral microenvironment in which HCC develops by eliminating hepatic senescent cells and activated fibroblasts. The gene discussed is BCL2L1; the disease is hepatocellular carcinoma.